Literature DB >> 4065186

Bronchorelaxation and plasma histamine after salbutamol inhalation.

I Macquin, A Harf, F Zerah, C Sabatier, F Lhoste.   

Abstract

Plasma histamine in 8 normal subjects was measured before and after inhalation of carbachol to induce a 50% fall in specific airway conductance (SGaw). The measurements were repeated 5 min after inhalation of salbutamol or placebo. No significant change in plasma histamine occurred after placebo or carbachol inhalation, despite the persistent induced bronchospasm after the latter treatment. In contrast, plasma histamine was significantly increased from 0.25 to 0.43 ng/ml after salbutamol inhalation. Simultaneously, induced bronchospasm was relieved, from 51% to 103% of baseline SGaw. Thus, the relief of carbachol-induced bronchospasm by salbutamol was associated with a rise in plasma histamine. Since salbutamol itself is a potent inhibitor of mast cell degranulation and histamine release, the present findings suggest that histamine may be released and sequestered within the lungs during carbachol-induced-bronchospasm, and also that desequestration of bronchoconstrictor mediators accumulated at the point of contact of bronchial smooth muscle may contribute to the relief of bronchospasm by salbutamol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065186     DOI: 10.1007/BF00607906

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  Increased sensitivity of the enzymatic isotopic assay of histamine: measurement of histamine in plasma and serum.

Authors:  R E Shaff; M A Beaven
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

2.  Role of mediators in allergic and nonallergic asthma in dogs with hyperreactive airways.

Authors:  C A Hirshman; J Peters; J Butler; J M Hanifin; H Downes
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-04

3.  Plasma histamine and catecholamines during carbachol-induced bronchoconstriction in normal subjects.

Authors:  I Macquin; F Zerah; A Harf; C Sabatier; F Lhoste
Journal:  J Allergy Clin Immunol       Date:  1984-09       Impact factor: 10.793

4.  Correction for nonlinearity of body flow plethysmograph.

Authors:  A Harf; G Atlan; H Lorino; S Deshayes; C Morin; D Laurent
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-03

5.  A sensitive and specific method for the determination of histomine in human whole blood and plasma.

Authors:  W Lorenz; H J Reimann; H Barth; J Kusche; R Meyer; A Doenicke; M Hutzel
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-06

6.  Exercise-induced asthma--clinical, physiological, and therapeutic implications.

Authors:  S Godfrey
Journal:  J Allergy Clin Immunol       Date:  1975-07       Impact factor: 10.793

7.  Measurement of plasma histamine: description of an improved method and normal values.

Authors:  J Dyer; K Warren; S Merlin; D D Metcalfe; M Kaliner
Journal:  J Allergy Clin Immunol       Date:  1982-08       Impact factor: 10.793

8.  Plasma histamine changes during provoked bronchospasm in asthmatic patients.

Authors:  K N Bhat; C M Arroyave; S R Marney; D D Stevenson; E M Tan
Journal:  J Allergy Clin Immunol       Date:  1976-12       Impact factor: 10.793

9.  A novel double-isotope technique for the enzymatic assay of plasma histamine: application to estimation of mast cell activation assessed by antigen challenge in asthmatics.

Authors:  M J Brown; P W Ind; R Causon; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1982-01       Impact factor: 10.793

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

View more
  1 in total

Review 1.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.